- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03543215
Can Staging Magnetic Resonance Imaging (MRI) Features Prognosticate Patients Presenting With Endometrial Cancer?
Aim: Assess the value of MRI features in predicting prognosis in patients with endometrial cancer
This study will examine the MRI features of women with confirmed endometrial cancer to see if textural features can prognosticate patients.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Aim: Assess the value of MRI features in predicting prognosis in patients with endometrial cancer
Background:
Endometrial cancer is the commonest gynaecological cancer in the United Kingdom. MR Imaging is used to provide pre-treatment local staging in Endometrial Cancer based on the FIGO staging system. This MRI stage is used by clinicians, in combination with pre-operative histology and clinical assessment of the patient, to counsel patients about their prognosis.
Currently the information obtained from the MRI study is largely anatomical and concerns the extent of local tumour spread at the time of diagnosis. Each stage under the FIGO system is associated with a prognosis based on data from the literature. Important prognostic indicators include the depth of tumour invasion in the uterine muscle (myometrium), invasion of the cervical stroma by tumour, spread to lymph node tissues and the histological sub-type of tumour present.
However, with ever improving MRI technology there are now newer sequences employed as part of the staging study which may potentially yield more information. In other cancer types, e.g. prostate, breast and liver, textural analysis of the tumour on pre-treatment imaging (CT/PET-CT/MRI) is being analysed to try and identify features which could be used as prognostic markers for patient outcome.
The Study:
All patients with confirmed cancer on histology will receive an Ultrasound and MRI as part of routine care. The MRI scan will include T1, T2, DWI and contrast enhanced sequences. Patients referred to Hammersmith Hospital from other trusts who are diagnosed with endometrial cancer will be approached for consent and enrolment into latter part of study. These patients will have had an MRI but may not have had all the sequences needed and may therefore require a further MRI scan with additional sequences. These images will be saved and analysed. Pathological findings (e.g. type and grade of cancer) will be correlated with the radiological results.
Definitive management of endometrial cancer includes a hysterectomy for most patients. Following surgery patients will continue with routine standard of care and follow up. Patients will be followed up for 5 years to provide 5 year survival data. Images from ultrasound and MRI pelvis will be analysed to see if they can predict the 5 year survival.
This prospective study will also be used to validate a retrospective model using MRI textural features in endometrial cancer patients.
Study Type
Enrollment (Anticipated)
Contacts and Locations
Study Locations
-
-
-
London, United Kingdom, W12 0HS
- Recruiting
- Queen Charlotte and Hammersmith Hospital
-
Principal Investigator:
- Sadaf Ghaem-Maghami
-
Principal Investigator:
- Andrea Rockall
-
Principal Investigator:
- Nishat Bharwani
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- All women presenting with a confirmed diagnosis of endometrial cancer
- Reviewed at the Specialist Gynaecology Oncology MDT
- Have MR Imaging and Hysterectomy specimens available for review.
Exclusion criteria:
- Anyone lacking capacity.
- <18years old.
- Pregnant.
- No MR Imaging available for review -- No pathology specimen available for review
Study Plan
How is the study designed?
Design Details
- Observational Models: Cohort
- Time Perspectives: Prospective
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
To assess the value of MRI features in predicting prognosis in patients with endometrial cancer using progression free survival (PFS) and overall survival (OS) as end points
Time Frame: 8 years (3 year data collection and 5 year follow up).
|
Assess features of pelvic MRIs (including (i) tumour image intensity, (II) shape, (III) texture and (IV) multiscale wavelet) and create a mathematical algorithm to predict prognostic outcome (5 year survival).
|
8 years (3 year data collection and 5 year follow up).
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Assess the correlation between imaging features and histopathological features.
Time Frame: 3 years
|
Assess textural features of pelvic MRI in conjunction with histopathology (type of tumour, grade LVSI, 'aggressiveness' of cancer
|
3 years
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 16HH3687 Radiomics EC
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Endometrial Neoplasms
-
University of Southern CaliforniaNational Cancer Institute (NCI)WithdrawnAtypical Endometrial Hyperplasia | Recurrent Endometrial Carcinoma | Endometrial Adenocarcinoma | Stage IA Endometrial Carcinoma | Stage IB Endometrial Carcinoma | Stage II Endometrial Carcinoma | Stage IIIA Endometrial Carcinoma | Stage IIIB Endometrial Carcinoma | Stage IIIC Endometrial Carcinoma | Stage... and other conditions
-
Case Comprehensive Cancer CenterTerminatedStage IV Endometrial Carcinoma | Stage III Endometrial Carcinoma | Stage II Endometrial Carcinoma | Stage I Endometrial CarcinomaUnited States
-
Sohag UniversityNot yet recruitingEndometrial Cancer and Endometrial HyperplasiaEgypt
-
CHU de ReimsUnknownEndometrial Hyperplasia and Endometrial CancersFrance
-
National Cancer Institute (NCI)CompletedRecurrent Endometrial Carcinoma | Endometrial Adenocarcinoma | Endometrial Clear Cell Carcinoma | Endometrial Papillary Serous Carcinoma | Stage IIIA Endometrial Carcinoma | Stage IIIB Endometrial Carcinoma | Stage IIIC Endometrial Carcinoma | Stage IVA Endometrial Carcinoma | Stage IVB Endometrial... and other conditionsCanada
-
Assistance Publique - Hôpitaux de ParisUniversité Montpellier; Ecole d'econmie de Paris (PSE)-Hospinnomics; Université...CompletedEndometrial Cancer Stage I | Endometrial Cancer Stage IIFrance
-
Peking University People's HospitalPeking University; Beihang UniversityRecruitingAtypical Endometrial Hyperplasia | Endometrial Carcinoma Stage IChina
-
Washington University School of MedicineMerck Sharp & Dohme LLCCompletedEndometrial Cancer | Endometrial Carcinoma | Neoplasms, EndometrialUnited States
-
Radboud University Medical CenterMaastricht University Medical Center; Erasmus Medical Center; Catharina Ziekenhuis... and other collaboratorsRecruitingEndometrial Cancer Recurrent | Endometrial Cancer Stage III | Endometrial Cancer Stage IVNetherlands
-
Imperial College LondonRecruitingEndometrial Hyperplasia | Endometrial Neoplasms | Endometrial Cancer | Endometrial PolypUnited Kingdom
Clinical Trials on Radiomics: Analysis of textural features of imaging (MRI and Ultrasound)
-
University Hospital, GhentRecruiting
-
University of Sao PauloFundação de Amparo à Pesquisa do Estado de São PauloCompleted
-
University of Southern CaliforniaNational Cancer Institute (NCI)RecruitingHealth Status Unknown | Elevated PSAUnited States
-
Tata Memorial CentreIndian Statistical Institute, KolkataActive, not recruiting
-
University of OuluOulu University Hospital; Kuopio University Hospital; University of Eastern FinlandCompletedKnee Osteoarthritis | Knee InjuriesFinland
-
Hospices Civils de LyonRecruitingAutoimmune Encephalitis Associated With Anti-CAPR2 AntibodiesFrance
-
Cedars-Sinai Medical CenterTerminated
-
Wake Forest University Health SciencesNational Cancer Institute (NCI)CompletedStage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Cognitive/Functional Effects | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIIC Breast Cancer | Recurrent Breast CancerUnited States
-
Hospices Civils de LyonCompletedAutoimmune EncephalitisFrance
-
IRCCS San RaffaeleUnknownPancreas AdenocarcinomaItaly